|
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer Clinical research trials and Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer. Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer  Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
For Condition: recurrent ovarian epithelial cancer,stage 4 ovarian epithelial cancer,peritoneal cavity cancer
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Gynecologic Oncology Group
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with recurrent or refractory ovarian or primary peritoneal cancer.
Details: OBJECTIVES: I. Estimate the antitumor activity of docetaxel in patients with paclitaxel- and platinum-resistant, recurrent or refractory, ovarian epithelial or primary peritoneal cancer who have failed on higher priority treatment protocols. II. Determine the nature and degree of toxicity of docetaxel in this patient population. PROTOCOL OUTLINE: Patients receive docetaxel as a 1 hour continuous intravenous infusion. Courses are repeated every 21 days. Treatment continues in the absence of unacceptable toxic effects or disease progression. All patients are followed every 3 months for 2 years, every 6 months for 3 years, and then until death. PROJECTED ACCRUAL: A total of 23-56 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed recurrent or refractory ovarian epithelial or peritoneal cancer Platinum resistant AND paclitaxel resistant - Progressed on or within 6 months of completing therapy with paclitaxel and platinum either alone or in combination Bidimensionally measurable disease (excludes ascites and pleural effusions) Brain metastases allowed provided that other measurable disease exists and brain lesions required no therapy for 6 months and are not life threatening Not eligible for higher priority GOG protocol --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: - See Disease Characteristics - Must have had at least 1 prior platinum based chemotherapeutic regimen containing carboplatin, cisplatin, or another organoplatinum compound - Must have had at least 1 prior paclitaxel based chemotherapeutic regimen 1 or 2 prior chemotherapy regimens containing platinum and paclitaxel allowed - Recovered from toxic effects - No prior docetaxel Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: Recovered from effects of recent surgery Other: - At least 3 weeks since any prior therapy directed at the malignant tumor - No prior cancer treatment that contraindicates this protocol therapy --Patient Characteristics-- Age: 18 and over Performance status: GOG 0-2 Life expectancy: At least 8 weeks Hematopoietic: - WBC at least 3,000/mm3 - Platelet count at least 100,000/mm3 - Granulocyte count at least 1,500/mm3 Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT/SGPT no greater than 1.5 times ULN - Alkaline phosphatase no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL Other: - No significant infection - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No history of allergic reaction to polysorbate 80 (e.g., etoposide or vitamin E) - No other invasive malignancies within the past 5 years except nonmelanoma skin cancer
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PeterRose, Study Chair, Gynecologic Oncology Group
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
United States
CCOP - Central Illinois
Springfield, Illinois, 62526
United States
NCIC-Clinical Trials Group
Kingston, Ontario, K7L 3N6
Canada
University of Colorado Cancer Center
Denver, Colorado, 80262
United States
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, 01655
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Keesler Medical Center - Keesler AFB
Keesler AFB, Mississippi, 39534-2576
United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
United States
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
United States
Johns Hopkins Oncology Center
Baltimore, Maryland, 21287
United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45219
United States
North Shore University Hospital
Manhasset, New York, 11030
United States
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
United States
Rush-Presbyterian-St. Luke's Medical Center
Chicago, Illinois, 60612
United States
University of Rochester Cancer Center
Rochester, New York, 14642
United States
CCOP - Columbia River Program
Portland, Oregon, 97213
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Abington Memorial Hospital
Abington, Pennsylvania, 19001
United States
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104
United States
University of Washington Medical Center
Seattle, Washington, 98195-6043
United States
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, 35294
United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033-0800
United States
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
Brookview Research, Inc.
Winston Salem, North Carolina, 27103
United States
Cleveland Clinic Cancer Center
Cleveland, Ohio, 44195
United States
Radiation Oncology Branch
Bethesda, Maryland, 20892
United States
MBCCOP - Hawaii
Honolulu, Hawaii, 96813
United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637
United States
CCOP - Evanston
Evanston, Illinois, 60201
United States
Women's Cancer Center
Palo Alto, California, 94304
United States
Cooper Hospital/University Medical Center
Camden, New Jersey, 08103
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
Medicine Branch
Bethesda, Maryland, 20892
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726
United States
Tacoma General Hospital
Tacoma, Washington, 98405
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
United States
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
United States
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107
United States
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107
United States
Washington University School of Medicine
St. Louis, Missouri, 63110
United States
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
United States
Cancer Center of Albany Medical Center
Albany, New York, 12208
United States
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston Salem, North Carolina, 27157-1082
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
CCOP - Kansas City
Kansas City, Missouri, 64131
United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
United States
Vincent T. Lombardi Cancer Research Center, Georgetown University
Washington D.C., District of Columbia, 20007
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612
United States
CCOP - Baptist Cancer Institute
Memphis, Tennessee, 38117
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5265
United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154
United States
State University of New York Health Sciences Center - Stony Brook
Stony Brook, New York, 11790-9832
United States
Cancer Center, University of Virginia HSC
Charlottesville, Virginia, 22908
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68131
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210
United States
CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
Tulsa, Oklahoma, 74136
United States
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma, 73190
United States
Additional Information:
Study ID Numbers: CDR0000066369; GOG-126J
Study Start Date: June 1998
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004037
Other Recurrent Ovarian Epithelial Cancer Studies:
1. Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer
2. CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
3. Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Advanced Ovarian Epithelial Cancer
4. Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
5. Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
Related Studies:
Other recurrent ovarian epithelial cancer Clinical Trials
Other Washington Clinical Trials
Other Tacoma Clinical Trials
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
|
|
|
|
|
|
|
|
